| First Author | Xu N | Year | 2016 |
| Journal | Oncotarget | Volume | 7 |
| Issue | 4 | Pages | 3884-96 |
| PubMed ID | 26646697 | Mgi Jnum | J:254805 |
| Mgi Id | MGI:6103740 | Doi | 10.18632/oncotarget.6461 |
| Citation | Xu N, et al. (2016) Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. Oncotarget 7(4):3884-96 |
| abstractText | Current guidelines for lung cancer treatment with EGFR tyrosine kinase inhibitors (TKI) include only patients with mutated EGFR, although some patients with wildtype EGFR (wt-EGFR) have exhibited positive responses to this therapy as well. Biomarkers predicting the benefit from EGFR-TKIs treatment remain to be determined for patients with wild-type EGFR.Here, we report that wt-EGFR overexpression transformed cells in vitro and induced tumorigenesis in vivo in transgenic mouse models. Wt-EGFR driven lung cancer was hypersensitive to TKI treatment in mouse model. Lung cancer patients with high-expression of wt-EGFR showed longer Overall Survival in comparison to low-expression patients after TKI treatment. Our data therefore suggest that treatment with EGFR inhibitors should be extended to include not only patients with mutated EGFR but also a subset of patients with overexpression of wt-EGFR. |
